# Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer

> **NCT05171530** · PHASE1 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 19 (estimated)

## Conditions studied

- HER2-negative Advanced Gastric Cancer

## Interventions

- **DRUG:** Lenvatinib plus taxane drugs

## Key facts

- **NCT ID:** NCT05171530
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-05
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2021-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05171530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05171530, "Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05171530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*